Compare
Nuvation Bio Inc. vs Enanta Pharmaceuticals Inc vs Spero Therapeutics, Inc. vs Aytu Biopharma, Inc
| Latest fiscal year | Nuvation Bio Inc. NUVB | Enanta Pharmaceuticals Inc ENTA | Spero Therapeutics, Inc. SPRO | Aytu Biopharma, Inc AYTU |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-09-30 | 2025-12-31 | 2026-06-30 |
| Revenue | $62.90M | $65.32M | $66.80M | $57.57M |
| Revenue growth (YoY) | +699.0% | -3.4% | +39.2% | -13.3% |
| Gross margin | n/a | n/a | n/a | 64.0% |
| Operating margin | -338.7% | -130.7% | 9.5% | -14.4% |
| Net margin | -325.3% | -125.4% | 12.8% | -24.8% |
| Net income | -$204.63M | -$81.89M | $8.57M | -$14.25M |
| EPS (Diluted) | -$0.60 | -$3.84 | $0.15 | n/a |
| Operating cash flow | -$173.43M | -$19.27M | -$12.62M | $3.28M |
| Free cash flow | n/a | -$32.17M | n/a | $3.25M |
| Cash & equivalents | $164.09M | $32.30M | $40.27M | $26.31M |
| Total assets | $594.82M | $280.73M | $68.92M | $105.01M |
| Total liabilities | $289.11M | $216.01M | $9.90M | n/a |
| Shareholders' equity | $305.72M | $64.72M | $59.02M | $35.27M |
| Return on year-end equity | -66.9% | -126.5% | 14.5% | -40.4% |
| Shares outstanding | 337.84M | 21.39M | 56.41M | 10.73M |
Revenue, most recent five fiscal years
| Fiscal year | Nuvation Bio Inc. | Enanta Pharmaceuticals Inc | Spero Therapeutics, Inc. | Aytu Biopharma, Inc |
|---|---|---|---|---|
| Latest | $62.90M Ended 2025-12-31 | $65.32M Ended 2025-09-30 | $66.80M Ended 2025-12-31 | $57.57M Ended 2026-06-30 |
| 1 year earlier | $7.87M Ended 2024-12-31 | $67.64M Ended 2024-09-30 | $47.98M Ended 2024-12-31 | $66.38M Ended 2025-06-30 |
| 2 years earlier | $0 Ended 2023-12-31 | $79.20M Ended 2023-09-30 | $103.78M Ended 2023-12-31 | $65.18M Ended 2024-06-30 |
| 3 years earlier | n/a | $86.16M Ended 2022-09-30 | $53.51M Ended 2022-12-31 | $107.40M Ended 2023-06-30 |
| 4 years earlier | n/a | $97.07M Ended 2021-09-30 | $18.26M Ended 2021-12-31 | $96.67M Ended 2022-06-30 |